Sign In
Buy ALIM
$5.54
+0 (+0%)
At Close: Dec 12, 2024
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q2 2022 Results - Earnings Call Transcript
08:23am, Saturday, 30'th Jul 2022
Alimera Sciences, Inc. (NASDAQ:ALIM ) Q2 2022 Earnings Conference Call July 27, 2022 9:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President & Chief Executive
Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates
12:45pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 26.23% and 8.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences to Report Second Quarter 2022 Financial Results on Wednesday, July 27, 2022, and Provide Corporate Update
02:34pm, Friday, 22'nd Jul 2022 GlobeNewswire Inc.
Conference Call to be held Wednesday July 27, at 9:00am Eastern Time Conference Call to be held Wednesday July 27, at 9:00am Eastern Time
Alimera Announces Pricing and Reimbursement of Uveitis Indication Granted for ILUVIEN® in France
12:00pm, Friday, 22'nd Jul 2022 GlobeNewswire Inc.
Partner Horus Pharma to launch ILUVIEN for non-infectious uveitis affecting the posterior segment indication later in Q3 Partner Horus Pharma to launch ILUVIEN for non-infectious uveitis affecting the
Alimera Sciences to Report Second Quarter 2022 Financial Results on Wednesday, July 27, 2022, and Provide Corporate Update
10:34am, Friday, 22'nd Jul 2022
Conference Call to be held Wednesday July 27, at 9:00am Eastern Time Conference Call to be held Wednesday July 27, at 9:00am Eastern Time
Alimera Announces Data to Be Highlighted In Scientific Programming At Annual Congress
12:00pm, Wednesday, 13'th Jul 2022 GlobeNewswire Inc.
ILUVIEN® data to be presented onsite at the annual American Society of Retina Specialists (ASRS) conference. ILUVIEN® data to be presented onsite at the annual American Society of Retina Specialists
Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy
12:00pm, Friday, 08'th Jul 2022 GlobeNewswire Inc.
ILUVIEN receives approval and pricing for non-infectious uveitis affecting the posterior segment indication in July; launch to follow ILUVIEN receives approval and pricing for non-infectious uveitis a
Phase III Clinical Study IND Accepted in China for Alimera’s Fluocinolone Acetonide Intravitreal Implant
12:03pm, Wednesday, 08'th Jun 2022 GlobeNewswire Inc.
ATLANTA, June 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partn
Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN® Use for IOP Outcomes
12:03pm, Thursday, 12'th May 2022 GlobeNewswire Inc.
Recently presented data further demonstrate steroid challenge is highly predictive of IOP response post-FAc regardless of steroid choice Recently presented data further demonstrate steroid challenge i
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
01:15pm, Monday, 09'th May 2022 Zacks Investment Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -26.87% and 8.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences, Inc (ALIM) CEO Richard Eiswirth on Q1 2022 Results - Earnings Call Transcript
11:42am, Monday, 09'th May 2022
Alimera Sciences, Inc (NASDAQ:ALIM ) Q1 2022 Earnings Conference Call May 9, 2022 9:00 AM ET Company Participants Scott Gordon - CORE IR Richard Eiswirth - President and Chief Executive Officer Phil J
Alimera Sciences to Report First Quarter 2022 Financial Results on Monday, May 9, 2022, and Provide Corporate Update
12:00pm, Friday, 06'th May 2022 GlobeNewswire Inc.
Conference Call to be held the same day at 9:00am Eastern Time Conference Call to be held the same day at 9:00am Eastern Time
Ocugen (OCGN) Reports Q1 Loss, Misses Revenue Estimates
11:45am, Friday, 06'th May 2022 Zacks Investment Research
Ocugen (OCGN) delivered earnings and revenue surprises of -280% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences to Report First Quarter 2022 Financial Results on Monday, May 9, 2022, and Provide Corporate Update
08:00am, Friday, 06'th May 2022
Conference Call to be held the same day at 9:00am Eastern Time Conference Call to be held the same day at 9:00am Eastern Time
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
09:55pm, Thursday, 05'th May 2022 Zacks Investment Research
Celldex (CLDX) delivered earnings and revenue surprises of -6.52% and 76.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
